Faricimab for macular oedema secondary to retinal vein occlusion


featured image

Faricimab is currently in clinical development for the treatment of macular oedema resulting from retinal vein occlusion (RVO). RVO is where a blockage happens in a vein in the back of the eye, stopping blood flow.

Indications: Retinal Vein Occlusion
Therapeutic Areas: Ophthalmology
Year: 2022

Faricimab is currently in clinical development for the treatment of macular oedema resulting from retinal vein occlusion (RVO). RVO is where a blockage happens in a vein in the back of the eye, stopping blood flow. Macular oedema is where fluid collects in the macula (area in the centre of the back of the eye important in detecting light to see things). This happens because the fluid cannot flow through the blocked veins. The build-up of fluid damages the eye and can result in irreversible vision problems. Faricimab is expected to reduce the treatment burden for patients as injections will be given less frequently than the treatments currently licensed.